Santiago Arroyo Sells 7,689 Shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Stock

Share on StockTwits

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) SVP Santiago Arroyo sold 7,689 shares of the company’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $30.03, for a total value of $230,900.67. Following the transaction, the senior vice president now directly owns 27,265 shares in the company, valued at $818,767.95. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Santiago Arroyo also recently made the following trade(s):

  • On Tuesday, January 21st, Santiago Arroyo sold 1,235 shares of Momenta Pharmaceuticals stock. The shares were sold at an average price of $30.08, for a total value of $37,148.80.

NASDAQ:MNTA opened at $31.88 on Friday. The firm has a market capitalization of $3.16 billion, a price-to-earnings ratio of -14.69 and a beta of 2.01. Momenta Pharmaceuticals, Inc. has a 1-year low of $9.51 and a 1-year high of $32.37. The business’s fifty day moving average price is $26.17 and its 200 day moving average price is $17.38.

Several research firms recently weighed in on MNTA. Wells Fargo & Co began coverage on Momenta Pharmaceuticals in a research report on Wednesday, November 6th. They set an “outperform” rating on the stock. SunTrust Banks upped their price target on Momenta Pharmaceuticals to and gave the company a “buy” rating in a research report on Wednesday, January 15th. ValuEngine lowered Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, December 24th. Stifel Nicolaus reissued a “buy” rating and set a $43.00 price target (up from $29.00) on shares of Momenta Pharmaceuticals in a research report on Monday, January 27th. Finally, Piper Sandler upped their price target on Momenta Pharmaceuticals from to in a research report on Wednesday, February 5th. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $31.79.

Large investors have recently bought and sold shares of the stock. Bank of America Corp DE raised its position in Momenta Pharmaceuticals by 53.0% during the second quarter. Bank of America Corp DE now owns 177,782 shares of the biotechnology company’s stock valued at $2,215,000 after buying an additional 61,579 shares during the period. Morgan Stanley raised its position in Momenta Pharmaceuticals by 709.7% during the second quarter. Morgan Stanley now owns 460,537 shares of the biotechnology company’s stock valued at $5,733,000 after buying an additional 403,661 shares during the period. UBS Asset Management Americas Inc. raised its position in Momenta Pharmaceuticals by 19.8% during the second quarter. UBS Asset Management Americas Inc. now owns 59,794 shares of the biotechnology company’s stock valued at $744,000 after buying an additional 9,876 shares during the period. Nuveen Asset Management LLC acquired a new position in Momenta Pharmaceuticals during the second quarter valued at $4,751,000. Finally, Peregrine Capital Management LLC raised its position in Momenta Pharmaceuticals by 3.4% during the third quarter. Peregrine Capital Management LLC now owns 832,627 shares of the biotechnology company’s stock valued at $10,791,000 after buying an additional 27,377 shares during the period. 97.03% of the stock is currently owned by hedge funds and other institutional investors.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.

Recommended Story: Mutual Funds

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.